MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN

Author:

Xue Xinying12,Liu Yuxia3,Wang Yong1,Meng Mingming4,Wang Kaifei2,Zang Xuefeng5,Zhao Sheng6,Sun Xiaohua7,Cui Lei8,Pan Lei1,Liu Sanhong9

Affiliation:

1. Department of Special Medical Treatment-Respiratory Disease, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

2. Department of Respiratory Diseases of Chinese PLA General Hospital, Beijing, China

3. Department of Research, Peking Union Medical Collage Hospital, Beijing, China

4. Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

5. Department of Intensive Care Unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

6. Department of Cardiology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China

7. Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China

8. Department of Central Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

9. Shanghai Institute of Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3